

Virginia Hernandez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3887320/publications.pdf>

Version: 2024-02-01

26
papers

6,226
citations

430442

18
h-index

552369

26
g-index

26
all docs

26
docs citations

26
times ranked

5927
citing authors

#	ARTICLE	IF	CITATIONS
1	EAU Guidelines on Non-muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. <i>European Urology</i> , 2017, 71, 447-461.	0.9	1,594
2	Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. <i>European Urology</i> , 2017, 71, 462-475.	0.9	1,241
3	European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. <i>European Urology</i> , 2021, 79, 82-104.	0.9	1,152
4	European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62	0.9	936
5	Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review. <i>European Urology</i> , 2017, 72, 801-813.	0.9	205
6	European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. <i>European Urology</i> , 2021, 79, 480-488.	0.9	198
7	The Impact of the Extent of Lymphadenectomy on Oncologic Outcomes in Patients Undergoing Radical Cystectomy for Bladder Cancer: A Systematic Review. <i>European Urology</i> , 2014, 66, 1065-1077.	0.9	164
8	The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma. <i>European Urology</i> , 2022, 81, 95-103.	0.9	158
9	Key Steps in Conducting Systematic Reviews for Underpinning Clinical Practice Guidelines: Methodology of the European Association of Urology. <i>European Urology</i> , 2018, 73, 290-300.	0.9	128
10	Risk Stratification Tools and Prognostic Models in Non-muscle-invasive Bladder Cancer: A Critical Assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel. <i>European Urology Focus</i> , 2020, 6, 479-489.	1.6	72
11	The Importance of Hospital and Surgeon Volume as Major Determinants of Morbidity and Mortality After Radical Cystectomy for Bladder Cancer: A Systematic Review and Recommendations by the European Association of Urology Muscle-invasive and Metastatic Bladder Cancer Guideline Panel. <i>European Urology Oncology</i> , 2020, 3, 131-144.	2.6	61
12	Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel Study. <i>European Urology Oncology</i> , 2021, 4, 182-191.	2.6	54
13	External validation and applicability of the EORTC risk tables for non-muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2011, 29, 409-414.	1.2	52
14	Oncological and functional outcomes of sexual function-preserving cystectomy compared with standard radical cystectomy in men: A systematic review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 539.e17-539.e29.	0.8	43
15	Long-term oncological outcomes of an active surveillance program in recurrent low grade Ta bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 165.e19-165.e23.	0.8	40
16	European Association of Urology Guidelines on Primary Urethral Carcinoma—2020 Update. <i>European Urology Oncology</i> , 2020, 3, 424-432.	2.6	28
17	Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 440-448.	0.8	27
18	Conflict of Evidence: Resolving Discrepancies When Findings from Randomized Controlled Trials and Meta-analyses Disagree. <i>European Urology</i> , 2017, 71, 811-819.	0.9	23

#	ARTICLE	IF	CITATIONS
19	Influence of androgen deprivation therapy on the severity of COVID-19 in prostate cancer patients. Prostate, 2021, 81, 1349-1354.	1.2	15
20	Effect of hospital volume on 90-day mortality after radical cystectomy for bladder cancer in Spain. World Journal of Urology, 2020, 38, 1221-1228.	1.2	9
21	Indication for a Single Postoperative Instillation of Chemotherapy in Non-muscle-invasive Bladder Cancer: What Factors Should Be Considered?. European Urology Focus, 2018, 4, 525-528.	1.6	8
22	The value of tumour weight as a predictive factor for recurrence and progression in non-muscle invasive bladder cancer. Scandinavian Journal of Urology, 2020, 54, 40-45.	0.6	7
23	T1G1 Bladder Cancer: Prognosis for this Rare Pathological Diagnosis Within the Non-muscle-invasive Bladder Cancer Spectrum. European Urology Focus, 2022, .	1.6	4
24	Weight of the resected specimen after transurethral resection as a new predictive variable for recurrence of non-muscle-invasive bladder tumour. BJU International, 2013, 111, E196-201.	1.3	3
25	A comprehensive analysis of cost of an active surveillance cohort compared to radical prostatectomy as primary treatment for prostate cancer. World Journal of Urology, 2019, 37, 1297-1303.	1.2	3
26	Prostate cancer adverse pathology reclassification in patients undergoing active surveillance in a long-term follow-up series. Prostate, 2020, 80, 209-213.	1.2	1